US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction

RIDGEFIELD, Conn. and INDIANAPOLIS, Jan. 11, 2021 /PRNewswire/ -- The U.S.   Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance ® (empagliflozin) which is being investigated as a potential new treatment to reduce the risk of cardiovascular death